<DOC>
	<DOCNO>NCT02792829</DOCNO>
	<brief_summary>The study conduct adult healthy participant consist two phase : Prerandomization Randomization . The Prerandomization Phase consist 2 period : Screening Period Baseline Period . The Randomization Phase consist 2 Periods ( 6 day long ) separate 1-day long Baseline Period End Treatment ( EOT ) Period . A total 60 participant enrol one three arm . Arms 1 3 consist 2 sequence , Arm 2 consist 4 sequence ( incomplete block design 2 factor [ number capsule whether water apple juice use vehicle ] ) . Each participant randomize one 8 sequence .</brief_summary>
	<brief_title>Crossover Study Evaluate Relative Bioavailability Palatability Lenvatinib Suspension Compared Capsule Formulation Adult Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . Healthy male female participant age great equal 18 year less equal 55 year old time inform consent 2 . Nonsmokers smoker smoke 10 cigarette per day 3 . BMI great equal 18 less equal 32 kg/m2 screen 4 . Adequate liver function , define : bilirubin le equal 1.5 X upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) less equal 1.5 X ULN 5 . Adequate renal function define creatinine clearance great 70 mL/min calculate use Cockcroft Gault formula 6 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ BhCG ] test minimum sensitivity 25 IU/L , equivalent unit BhCG . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 7 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) 8 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( eg , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , participant must agree use doublebarrier method describe becomes sexually active study period 30 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week dose must continue use contraceptive study 30 day study drug discontinuation . 9 . Male participant must successful vasectomy ( confirm azoospermia ) , female partner must meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . No sperm donation allow study period 30 day study drug discontinuation . 10 . Provide write informed consent 11 . Willing able comply aspect protocol 1 . Clinically significant illness require medical treatment within 8 week prior , clinically significant infection require medical treatment within 4 week prior dose 2 . Evidence disease may influence outcome study , within 4 week prior dose ; eg , psychiatric disorder disorder gastrointestinal ( GI ) tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , participant congenital abnormality metabolism 3 . Any history surgery may affect PK profile lenvatinib eg , hepatectomy , nephrotomy , digestive organ resection , screen baseline 4 . Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign , electrocardiogram ( ECG ) finding , laboratory test result require medical treatment screen baseline 5 . Prolonged QTcF interval ( QTcF great 450 m ) demonstrate ECG screen baseline 6 . Known history clinically significant drug allergy Screening Baseline 7 . Known history food allergy presently experience significant seasonal perennial allergy Screening Baseline 8 . Known history sensitivity component test product 9 . Known human immunodeficiency virus ( HIV ) positive screen 10 . Active viral hepatitis ( A , B , C ) demonstrate positive serology screen 11 . History drug alcohol dependency abuse within 2 year prior screen , positive urine drug test breath alcohol test Screening Baseline 12 . Engagement strenuous exercise within 2 week prior checkin ( eg , marathon runner , weight lifter ) 13 . Any medical condition would make participant opinion investigator sponsor , unsuitable study , opinion investigator , likely complete study reason 14 . Intake herbal preparation contain St. John 's Wort within 4 week prior dose 15 . Use prescription drug within 4 week prior dose 16 . Intake overthecounter ( OTC ) medication within 2 week prior dose 17 . Receipt blood product within 4 week , donation blood within 8 week , donation plasma within 1 week prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bioavailability Lenvatinib suspension</keyword>
	<keyword>Palatability Lenvatinib suspension</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>Lenvima</keyword>
	<keyword>E7080</keyword>
	<keyword>Capsule formulation</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>